Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon

Background: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin. Aim: To compare survi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Conté L,Guillermo, Figueroa M,Gastón, Lois V,Vivianne, Cabrera C,María Elena, León R,Alvaro, García L,Hernán, Rojas R,Hernán
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2008
Materias:	Kidney failure, chronic Multiple myeloma Neoplasm staging
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872008000100001
record_format	dspace
spelling	oai:scielo:S0034-988720080001000012008-04-30Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-SalmonConté L,GuillermoFigueroa M,GastónLois V,VivianneCabrera C,María ElenaLeón R,AlvaroGarcía L,HernánRojas R,Hernán Kidney failure, chronic Multiple myeloma Neoplasm staging Background: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin. Aim: To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. Material and methods: Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems. Results: Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11% were in stage I 12% in stage II and 73% in stage III According to ISS, 34% were in stage I 35% in stage II and 31% in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival. Conclusions: The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality (Rev Méd Chile 2008; 136: 7-12)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.1 20082008-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100001es10.4067/S0034-98872008000100001
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Kidney failure, chronic Multiple myeloma Neoplasm staging
spellingShingle	Kidney failure, chronic Multiple myeloma Neoplasm staging Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
description	Background: Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin. Aim: To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. Material and methods: Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems. Results: Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11% were in stage I 12% in stage II and 73% in stage III According to ISS, 34% were in stage I 35% in stage II and 31% in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival. Conclusions: The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality (Rev Méd Chile 2008; 136: 7-12)
author	Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán
author_facet	Conté L,Guillermo Figueroa M,Gastón Lois V,Vivianne Cabrera C,María Elena León R,Alvaro García L,Hernán Rojas R,Hernán
author_sort	Conté L,Guillermo
title	Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
title_short	Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
title_full	Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
title_fullStr	Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
title_full_unstemmed	Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon
title_sort	valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: comparación con el sistema de durie-salmon
publisher	Sociedad Médica de Santiago
publishDate	2008
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100001
work_keys_str_mv	AT contelguillermo valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT figueroamgaston valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT loisvvivianne valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT cabreracmariaelena valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT leonralvaro valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT garcialhernan valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon AT rojasrhernan valorpronosticodelnuevosistemadeetapificacioninternacionalenmielomamultiplecomparacionconelsistemadeduriesalmon
_version_	1718436356067164160

Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon

Ejemplares similares